Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study

被引:9
作者
Bensimhon, Daniel [1 ]
Weintraub, William S. [2 ]
Peacock, William Frank [3 ]
Alexy, Tamas [4 ]
McLean, Dalton [1 ]
Haas, Donald [5 ]
Deering, Kathleen L. [6 ]
Millar, Stefanie J. [7 ]
Goodwin, Matthew M. [8 ]
Mohr, John F. [8 ]
机构
[1] Cone Hlth, Greensboro, NC 27401 USA
[2] MedStar Hlth Res Inst, Hyattsville, MD 20782 USA
[3] Ben Taub Hosp, Houston, TX 77030 USA
[4] Univ Minnesota, Minneapolis, MN 55455 USA
[5] Abington Hosp, Abington, PA 19001 USA
[6] EPI Q Inc, Oak Brook, IL 60604 USA
[7] ICON Clin Res, North Wales, PA 19454 USA
[8] scPharmaceuticals, Burlington, MA 01803 USA
关键词
congestion; diuretics; emergency department; Furosemide; heart failure; subcutaneous; SUBCUTANEOUS FUROSEMIDE; THERAPY; MEDICARE; BURDEN; IMPACT;
D O I
10.2217/fca-2023-0071
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plain language summary: reduced heart failure costs with subcutaneous Furoscix at home versus in-hospital intravenous diureticsWhat is this article about? In heart failure (HF), the heart cannot pump as well as it should. This causes blood to back up in the vessels that return blood to the heart. Fluid leaks from these vessels and collects in vital organs such as the lungs. This fluid build-up is called congestion. Congestion causes symptoms such as shortness of breath, tiredness and leg swelling. Furoscix is a prescription medicine, a diuretic, that treats congestion. Diuretics help get rid of extra fluid by increasing urination. Congestion is usually managed with oral diuretics, but sometimes congestion cannot be controlled by oral diuretics and patients may have to spend several days at a clinic or hospital to receive diuretics given through a vein (intravenous or IV). Furoscix is a new formulation of furosemide, a common diuretic, and is delivered into the skin (subcutaneous) by a self-administered pump instead of through an IV. Our investigation aimed to answer two questions Can Furoscix be given to patients at home instead of in the hospital with IV diuretics? Is there a cost savings to using Furoscix? Instead of being admitted to the hospital for IV diuretics, HF patients with worsening congestion who came to the emergency department were sent home to receive Furoscix 80 mg/10 ml 5-h subcutaneous infusion for & LE;7 days. 30-day costs related to HF in these patients were compared with costs from similar group of patients previously hospitalized for IV diuretics. What were the results & what do they mean? In patients who needed to be admitted to the hospital for IV diuretics, Furoscix given at home instead reduced congestion and resulted in significant cost savings. Patients with heart failure, who are not getting relief with oral diuretics, can be treated with Furoscix at home without having to be admitted to the hospital for IV diuretics. Use of Furoscix instead of IV furosemide can save money to the healthcare system. Aim: Compare heart failure (HF) costs of Furoscix use at home compared with inpatient intravenous (IV) diuresis. Patients & methods: Prospective, case control study of chronic HF patients presenting to emergency department (ED) with worsening congestion discharged to receive Furoscix 80 mg/10 ml 5-h subcutaneous infusion for & LE;7 days. 30-day HF-related costs in Furoscix group derived from commercial claims database compared with matched historical patients hospitalized for Results: Of 24 Furoscix patients, 1 (4.2%) was hospitalized in 30-day period. Sixty-six control patients identified and were well-matched for age, sex, ejection fraction (EF), renal function and other comorbidities. Furoscix patients had reduced mean per patient HF-related healthcare cost of $16,995 (p < 0.001). Conclusion: Furoscix use was associated with significant reductions in 30-day HF-related healthcare costs versus matched hospitalized controls. Tweetable abstractCompared with a historical matched cohort of patients admitted to hospital for & LE;72 h to receive intravenous (IV) furosemide, use of Furoscix at home resulted in a per patient reduction in heart failure-related costs of $16,995.
引用
收藏
页码:385 / 396
页数:12
相关论文
共 23 条
  • [1] Outpatient Intravenous Diuretic Therapy for Acute Heart Failure: A Simplified Solution to a Formidable Problem
    Al-Ani, Mohammad A.
    Schwartz, Cody
    Winchester, David
    Barry, Julia
    Cerda, Martin
    Aranda, Juan M., Jr.
    Ahmed, Mustafa M.
    [J]. JOURNAL OF CARDIAC FAILURE, 2020, 26 (09) : 800 - 801
  • [2] Ambulatory Treatment of Worsening Heart Failure With Intravenous Loop Diuretics: A Four-Year Experience
    Buckley, Leo F.
    Stevenson, Lynne W.
    Cooper, Irene M.
    Knowles, Danielle M.
    Matta, Lina
    Molway, David W.
    Navarro-Velez, Kristina
    Rhoten, Megan N.
    Shea, Elaine L.
    Stern, Gretchen M.
    Weintraub, Joanne R.
    Young, Michelle A.
    Mehra, Mandeep R.
    Desai, Akshay S.
    [J]. JOURNAL OF CARDIAC FAILURE, 2020, 26 (09) : 798 - 799
  • [3] Is Hospital Admission for Heart Failure Really Necessary? The Role of the Emergency Department and Observation Unit in Preventing Hospitalization and Rehospitalization
    Collins, Sean P.
    Pang, Peter S.
    Fonarow, Gregg C.
    Yancy, Clyde W.
    Bonow, Robert O.
    Gheorghiade, Mihai
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (02) : 121 - 126
  • [4] The cost impact to Medicare of shifting treatment of worsening heart failure from inpatient to outpatient management settings
    Fitch, Kathryn
    Lau, Jocelyn
    Engel, Tyler
    Medicis, Joseph J.
    Mohr, John F.
    Weintraub, William S.
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 855 - 863
  • [5] Subcutaneous furosemide as palliative treatment in patients with advanced and terminal-phase heart failure
    Galindo-Ocana, Javier
    Romero-Mena, Juan
    Ramon Castillo-Ferrando, Juan
    Aguilera-Gonzalez, Carmen
    Bernabeu-Wittel, Maximo
    Ollero-Baturone, Manuel
    [J]. BMJ SUPPORTIVE & PALLIATIVE CARE, 2013, 3 (01) : 7 - +
  • [6] Development of a predictive model of hospitalization in primary care patients with heart failure
    Garcia-Olmos, Luis
    Aguilar, Rio
    Lora, David
    Carmona, Montse
    Alberquilla, Angel
    Garcia-Caballero, Rebeca
    Sanchez-Gomez, Luis
    Rodriguez Salvanes, Francisco
    Garrido Elustondo, Sofia
    Batlle, Maurice
    Porro, Carlos
    Gutierrez Humanes, Cristina
    Monge, Elena
    Lopez Rodriguez, Ana Belen
    Benito, Luis
    Banos, Nicolas
    Simon, Amaya
    Martinez Alvarez, Miguel Angel
    Garcia Benito, Cristina
    Velilla Celma, Ma Angeles
    Blesa Mayordomo, Marisol
    Pedraz Garcia, Isabel
    Garcia Gutierrez, David
    Serrano Vazquez, Angel
    Jarabo Sanchez, Maria Jose
    Sanchez Rodriguez, Esperanza
    Aller Martin, Pilar
    Delgado Pinto, Genoveva
    Martin Sanz, Amparo
    Chantal Costero, Rosario
    Sevillano Fuentes, Eva
    Nunez Portela, Belen
    Urena Llacer, Remedios
    [J]. PLOS ONE, 2019, 14 (08):
  • [7] Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure
    Gilotra, Nisha A.
    Princewill, Oluseyi
    Marino, Bonnie
    Okwuosa, Ike S.
    Chasler, Jessica
    Almansa, Johana
    Cummings, Abby
    Rhodes, Parker
    Chambers, Julianne
    Cuomo, Kimberly
    Russell, Stuart D.
    [J]. JACC-HEART FAILURE, 2018, 6 (01) : 65 - 70
  • [8] In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States
    Greene, Stephen J.
    Triana, Taylor S.
    Ionescu-Ittu, Raluca
    Burne, Rebecca M.
    Guerin, Annie
    Borentain, Maria
    Kessler, Paul D.
    Tugcu, Aylin
    DeSouza, Mary M.
    Felker, G. Michael
    Chen, Lei
    [J]. JACC-HEART FAILURE, 2020, 8 (11) : 943 - 953
  • [9] Outpatient Intravenous Diuretic Therapy for Heart Failure in the United States
    Greene, Stephen J.
    Wilson, Lauren E.
    Abbasi, Siddique A.
    Yusuf, Akeem A.
    Hammill, Bradley G.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1101 - 1103
  • [10] Outpatient Worsening Heart Failure as a Target for Therapy A Review
    Greene, Stephen J.
    Mentz, Robert J.
    Felker, G. Michael
    [J]. JAMA CARDIOLOGY, 2018, 3 (03) : 252 - 259